INRLF News and Press, Valneva Se Ord From 03/31/23

Saint - Herblain ( France), March 31 , 20 2 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 30 2023, of its 2022 Universal Registration Document (URD) with the French Financi...

Saint Herblain (France), March 30, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today it will present on its single-shot chikungunya vaccine candidate, VLA1553, and host a roundtable on Zika vaccines next week at the 23 rd Worl...

2023-03-23 13:25:03 ET Valneva SE (VALN) Q4 2022 Earnings Conference Call March 23, 2023 10:00 a.m. ET Company Participants Joshua Drumm - Vice President of Investor Relations Thomas Lingelbach - Chief Executive Officer Peter Buhler - Chief Financial Officer ...

2023-03-23 09:55:26 ET The following slide deck was published by Valneva SE in conjunction with their 2022 Q4 earnings call. For further details see: Valneva SE 2022 Q4 - Results - Earnings Call Presentation

Total revenue s of €3 6 1 . 3 million in 202 2 compared to €348 . 1 million in 2021 Driven by product sales of €114.8 million (82.3% increase compared to 2021), including €85.2 million of trave...

Saint - Herblain ( France), March 2 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced additional data from remaining clinical studies and an update on regulatory submissions for its inactiva...

Saint- Herb lain (France) , March 1 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors ...

Saint - Herblain ( France), February 20 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Administration (FDA) has completed a filing review of its Biologics Lice...

New York & Saint- Herblain (France), February 17, 2023 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announce that Pfizer, as the study sponsor, has decided to discontinue a significant percentage of participants in the U.S. who had been e...

Total revenue s of €3 6 1 . 3 million in 202 2 were ahead of previously communicated guidance of €340 million to €360 million 1 (compared to €348 . 1 million in 2021) Driven...